<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Pediatric Ophthalmology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Pediatric Ophthalmology</journal-title><trans-title-group xml:lang="ru"><trans-title>Российская педиатрическая офтальмология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1993-1859</issn><issn publication-format="electronic">2412-432X</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">37588</article-id><article-id pub-id-type="doi">10.17816/rpoj37588</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Use of the medicine Alphagan®P in the treatment of paediatric glaucoma</article-title><trans-title-group xml:lang="ru"><trans-title>Применение препарата Альфаган®Р в лечении глаукомы у детей</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Katargina</surname><given-names>Ljudmila Anatol'evna</given-names></name><name xml:lang="ru"><surname>Катаргина</surname><given-names>Людмила Анатольевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, заместитель директора по научной работе</p></bio><email>katargina@igb.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mazanova</surname><given-names>Ekaterina Viktorovna</given-names></name><name xml:lang="ru"><surname>Мазанова</surname><given-names>Екатерина Викторовна</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., научный сотрудник отдела патологии глаз у детей</p></bio><email>dho@igb.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">The Helmholtz Moscow Research Institute of Eye Diseases</institution></aff><aff><institution xml:lang="ru">ФГБУ «Московский НИИ глазных болезней им. Гельмгольца» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2014-09-15" publication-format="electronic"><day>15</day><month>09</month><year>2014</year></pub-date><volume>9</volume><issue>3</issue><issue-title xml:lang="en">VOL 9, NO3 (2014)</issue-title><issue-title xml:lang="ru">ТОМ 9, №3 (2014)</issue-title><fpage>10</fpage><lpage>13</lpage><history><date date-type="received" iso-8601-date="2020-07-21"><day>21</day><month>07</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2014, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2014, ООО "Эко-Вектор"</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">ООО "Эко-Вектор"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://ruspoj.com/1993-1859/article/view/37588">https://ruspoj.com/1993-1859/article/view/37588</self-uri><abstract xml:lang="en"><p>The article presents the experience of one of the modern anti-hypertensive medicine, approved for use in children, Alphagan® P in various forms, stages of congenital and secondary glaucoma in children. Data obtained in this study allowed us to estimate the effectiveness of the drug as monotherapy and in combined appointment, a comparative analysis of the degree of IOP reduction at different stages and forms of paediatric glaucoma, including young children.</p></abstract><trans-abstract xml:lang="ru"><p>Представлен опыт применения одного из современных гипотензивных препаратов, разрешенных к применению у детей, - Альфаган® P - при различных формах и стадиях врожденной и вторичной глаукомы у детей. Полученные данные позволили оценить эффективность препарата в виде монотерапии и при комбинированном назначении, провести сравнительный анализ степени снижения внутриглазного давления при различных стадиях и формах глаукомы у детей, в том числе у детей младшего возраста.</p></trans-abstract><kwd-group xml:lang="en"><kwd>congenital glaucoma</kwd><kwd>secondary glaucoma</kwd><kwd>antiglaucomatous drugs</kwd><kwd>Alphagan-P®</kwd><kwd>intraocular pressure</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>врожденная глаукома</kwd><kwd>вторичная глаукома</kwd><kwd>антиглаукоматозные препараты</kwd><kwd>Альфаган® P</kwd><kwd>внутриглазное давление</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Аветисов Э.С., Ковалевский Е.И., Хватова А.В. Руководство по детской офтальмологию. М.: Медицина; 1987.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Moore W., Nischal K.K. Pharmacologic management of glaucoma in childhood. Paediatr. Drugs. 2007; 9(2): 71-9.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Coppens G., Stalmans I., Zeyen T., Casteels I. The safety and efficacy of glaucoma medication in the pediatric population. J. Pediatr. Ophthalmol. Strabismus. 2009. 46(1): 12-8.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Daubert G.P. Is brimonidine ophthalmic a safe therapy for infants? J. Clin. Pharmacol. Ther 2006; 31(3): 289-92.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Montero-de-Espinosa I., Marquez-de-Aracena R., Morales C. Ocular hypertension in children treated with brimonidine 0,2%. A clinical study. Arch. Soc. Esp. Oftalmol. 2006; 81(3): 155-9.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Bowman R.J., Cope J., Nischal K.K. Ocular and systemic side effects of brimonidine 0,2% eye drops (Alphagan) in children. Eye (Lond). 2004; 18(1): 24-6.</mixed-citation></ref></ref-list></back></article>
